Loading...
The 2024 update to the U.S. adult vaccination schedule includes both new products and adjustments to existing protocols. It is accompanied by an unusually critical editorial directed not at the vaccine recommendations themselves but at their increasingly complicated presentation.
Respiratory syncytial virus (RSV) has joined the ranks of vaccine-preventable infections, with Pfizer's Abrysvo and Glaxo's Arexvy both newly available for adults who are 60 or older; they are recommended especially for those with substantial comorbidities. In addition, Abrysvo is recommended in the last month of pregnancy to induce possibly lifesaving antibodies in neonates…